RS for 40-year-old, 1.5-cm node+ (1 node) ER+ IDC? No. of MammaPrint® (70-gene signature) assays ordered in past 1 y?
Would you order an Oncotype DX assay for a 40-year-old premenopausal woman with a 1.5-cm, ER-positive, HER2-negative IDC and 1 positive node?
Approximately how many MammaPrint® assays have you ordered in the past year?
I-SPY2 Trial (Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging And moLecular Analysis 2). NCT01042379
Mamounas EP et al. Association between the 21-gene Recurrence Score (RS) and benefit from adjuvant paclitaxel (Pac) in node-positive (N+), ER-positive breast cancer patients (pts): Results from NSABP B-28. San Antonio Breast Cancer Symposium 2012;Abstract S1-10.
Molecular profiling assays, the Rx PONDER trial of adjuvant endocrine therapy with or without chemotherapy for node-positive BC with Recurrence Score (RS) of 25 or lower and the association between metabolic syndrome and RS. Breast Cancer Update, Issue 2, 2013. Available at: http://www.researchtopractice.com/browse-by-tumor-types/breast-cancer/5jcbe/12/2/kathy-s-albain-md/molecular-profiling-assays-rx-ponde.
Rutgers E et al. The EORTC 10041/BIG 03-04 MINDACT trial is feasible: Results of the pilot phase. Eur J Cancer 2011;47(18):2742-9. Abstract
RxPonder: A phase III, randomized clinical trial of standard adjuvant endocrine therapy +/-chemotherapy in patients with 1-3 positive nodes, hormone receptor-positive and HER2-negative breast cancer with recurrence score (RS) of 25 or less. NCT01272037
Stemmer SM et al. The impact of the 21-gene Recurrence Score assay on clinical decision-making in node-positive (up to 3 positive nodes) estrogen receptor-positive breast cancer patients. Breast Cancer Res Treat 2013;140(1):83-92. Abstract